Legacy Capital Partners’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | $482K | Hold |
8,106
| – | – | 0.16% | 107 |
|
|
2021
Q4 | $589K | Sell |
8,106
-3,500
| -30% | -$241K | 0.19% | 99 |
|
|
2021
Q3 | $811K | Buy |
11,606
+2,000
| +21% | +$141K | 0.29% | 80 |
|
|
2021
Q2 | $661K | Buy |
9,606
+1,700
| +22% | +$114K | 0.24% | 87 |
|
|
2021
Q1 | $511K | Sell |
7,906
-250
| -3% | -$16.1K | 0.19% | 95 |
|
|
2020
Q4 | $475K | Sell |
8,156
-250
| -3% | -$15.1K | 0.19% | 96 |
|
|
2020
Q3 | $531K | Sell |
8,406
-15
| -0.2% | -$1.04K | 0.21% | 89 |
|
|
2020
Q2 | $648K | Sell |
8,421
-189
| -2% | -$14.5K | 0.28% | 75 |
|
|
2020
Q1 | $644K | Buy |
8,610
+412
| +5% | +$28.5K | 0.32% | 70 |
|
|
2019
Q4 | $533K | Sell |
8,198
-65
| -0.8% | -$4.23K | 0.21% | 89 |
|
|
2019
Q3 | $524K | Hold |
8,263
| – | – | 0.23% | 88 |
|
|
2019
Q2 | $558K | Buy |
8,263
+440
| +6% | +$28.9K | 0.25% | 82 |
|
|
2019
Q1 | $509K | Sell |
7,823
-935
| -11% | -$62.1K | 0.24% | 83 |
|
|
2018
Q4 | $548K | Hold |
8,758
| – | – | 0.29% | 74 |
|
|
2018
Q3 | $676K | Buy |
8,758
+350
| +4% | +$26.4K | 0.31% | 74 |
|
|
2018
Q2 | $596K | Sell |
8,408
-100
| -1% | -$7.06K | 0.29% | 77 |
|
|
2018
Q1 | $641K | Sell |
8,508
-90
| -1% | -$7.15K | 0.32% | 74 |
|
|
2017
Q4 | $616K | Sell |
8,598
-800
| -9% | -$60.8K | 0.3% | 70 |
|
|
2017
Q3 | $761K | Buy |
9,398
+300
| +3% | +$22.9K | 0.4% | 63 |
|
|
2017
Q2 | $644K | Sell |
9,098
-13,345
| -59% | -$888K | 0.35% | 68 |
|
|
2017
Q1 | $1.52M | Sell |
22,443
-8,384
| -27% | -$590K | 0.86% | 45 |
|
|
2016
Q4 | $2.21M | Sell |
30,827
-326
| -1% | -$24.2K | 1.34% | 29 |
|
|
2016
Q3 | $2.46M | Sell |
31,153
-1,250
| -4% | -$102K | 1.55% | 23 |
|
|
2016
Q2 | $2.7M | Sell |
32,403
-1,970
| -6% | -$175K | 1.68% | 20 |
|
|
2016
Q1 | $3.16M | Sell |
34,373
-275
| -0.8% | -$24.8K | 2.04% | 13 |
|
|
2015
Q4 | $3.51M | Buy |
34,648
+103
| +0.3% | +$10.7K | 2.25% | 11 |
|
|
2015
Q3 | $3.39M | Buy |
34,545
+2,250
| +7% | +$250K | 2.3% | 11 |
|
|
2015
Q2 | $3.78M | Buy |
32,295
+1,230
| +4% | +$134K | 2.46% | 5 |
|
|
2015
Q1 | $3.05M | Buy |
31,065
+2,320
| +8% | +$236K | 1.94% | 16 |
|
|
2014
Q4 | $2.71M | Buy |
28,745
+5,425
| +23% | +$561K | 1.73% | 18 |
|
|
2014
Q3 | $2.48M | Buy |
23,320
+1,600
| +7% | +$157K | 1.65% | 21 |
|
|
2014
Q2 | $1.8M | Buy |
21,720
+1,250
| +6% | +$97.3K | 1.17% | 30 |
|
|
2014
Q1 | $1.45M | Sell |
20,470
-6,300
| -24% | -$494K | 1.03% | 36 |
|
|
2013
Q4 | $2.01M | Sell |
26,770
-2,730
| -9% | -$190K | 1.43% | 24 |
|
|
2013
Q3 | $1.85M | Sell |
29,500
-3,250
| -10% | -$194K | 1.38% | 24 |
|
|
2013
Q2 | $1.68M | Buy |
+32,750
| New | +$1.71M | 1.28% | 25 |
|
Other funds holding GILD
Legacy Capital Partners's GILD Position: Q1 2022 in Review
Legacy Capital Partners held its Gilead Sciences (GILD) position steady in Q1 2022 at 8,106 shares worth $482K. The position accounts for 0.16% of the portfolio, ranked #107.
Legacy Capital Partners first reported a position in GILD in Q2 2013 and has held it in 36 quarters since. The position peaked at $3.78M in Q2 2015. 1,600 funds tracked by Wall St. Rank hold GILD as of Q1 2022.
- Legacy Capital Partners held 8,106 shares of Gilead Sciences worth $482K as of Q1 2022.
- Legacy Capital Partners left its Gilead Sciences share count unchanged in Q1 2022.
- Gilead Sciences made up 0.16% of Legacy Capital Partners's portfolio in Q1 2022, its #107 holding.
- Legacy Capital Partners first reported a position in Gilead Sciences in Q2 2013 and has held it in 36 quarters since.
- Legacy Capital Partners's Gilead Sciences position peaked at $3.78M in Q2 2015.
- 1,600 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2022.
Based on Legacy Capital Partners's 13F filing for Q1 2022, filed 11 Apr 2022.